A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
Crossref DOI link: https://doi.org/10.1007/s00280-017-3458-7
Published Online: 2017-10-16
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sato, Yasushi http://orcid.org/0000-0002-7971-6487
Hirakawa, Masahiro
Ohnuma, Hiroyuki
Takahashi, Minoru
Okamoto, Tetsuro
Okamoto, Koichi
Miyamoto, Hiroshi
Muguruma, Naoki
Furuhata, Tomohisa
Takemasa, Ichiro
Kato, Junji
Takayama, Tetsuji
License valid from 2017-10-16